Digital Pathology Market by Product (Software & Analytics, Scanners, Storage & Communication Systems, Services), by Application (Cancer Diagnosis, Drug Discovery & Development, Disease Research, Others (Education and training, clinical diagnostics for non-cancer disease, and veterinary/forensic pathology)), by End User (Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Academic & Research Institutes), by Deployment (On-Premise, Cloud-Based, Hybrid), and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035
St. Catharines, Ontario, 9 Nov 2026 — Vectomat Insights has published a new report titled ‘Digital Pathology Market by Product, Application, End User, Deployment, and Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035.’ The Global Digital Pathology market was valued at USD 1,378.5 Mn in 2025 and is projected to reach USD 4,175.6 Mn by 2035, growing at a CAGR of 11.72% during the forecast period 2026–2035, according to Vectomat Insights.
Software & Analytics holds the biggest slice of 2025 revenue at 42.0%, yet the money is now chasing the whole slide-to-sign-out workflow: Leica Biosystems won three FDA 510(k) clearances in August 2026, Roche agreed to buy PathAI in May 2026, and North America already accounts for 40.0% of global spend.
The Global Digital Pathology market was valued at USD 1,378.5 Mn in 2025 and is projected to reach USD 4,175.6 Mn by 2035, an 11.72% CAGR over 2026–2035, according to Vectomat Insights. North America leads with a 40.0% share. Software & Analytics is the largest product segment at 42.0%, while Storage & Communication Systems grow fastest, at 17.41% a year.
Key Insights Snapshot
| Metric | Value |
|---|---|
| Report Title | Global Digital Pathology Market Size, Share, Growth & Forecast By Product, Application, End User, and Deployment, 2026–2035 |
| Base Year Market Size | USD 1,378.5 Mn (2025) |
| Forecast Market Size | USD 4,175.6 Mn (2035) |
| CAGR | 11.72% |
| Forecast Period | 2026–2035 |
| Dominant Region | North America (40.0%) |
| Fastest-Growing Region | Asia Pacific |
| Dominant Segment | Software & Analytics (42.0%) |
| Dominant Application | Cancer Diagnosis |
| Report Format | |
| Publisher | Vectomat Insights |
What Diagnostics Leaders Need to Know About the Digital Pathology Market
Hospital CIOs: A fully digital pathology department generates petabytes, not terabytes, and Storage & Communication Systems is the fastest-growing product line in this market at a 17.41% CAGR. Budget the archive and network upgrade alongside the scanner, or the scanner sits idle behind a full server.
Laboratory Medical Directors: Leica Biosystems' FDA-cleared Aperio iQC DX flagged up to 24% more slide artifacts and cut hands-on review time by 69% in a Heidelberg study. Labs still running manual slide QC are paying in rescans and turnaround time that competitors have already removed.
Pharma R&D Heads: Pharma & Biotech Companies account for 30.0% of 2025 digital pathology revenue, and Drug Discovery & Development applications grow at 14.13% a year. Companion-diagnostic algorithms, the core of Roche's planned PathAI purchase, are becoming a launch requirement for biomarker-led oncology drugs, not an optional add-on.
Regulatory Affairs Directors: Proscia's August 2026 510(k) included a predetermined change control plan, letting it add scanners and displays without new submissions. Vendors without a PCCP strategy will move slower on every hardware update this decade.
Healthcare Investors: Two strategic exits in five months, Roche-PathAI at up to USD 1.05 Bn and Agilent-Proscia at up to USD 270 Mn, have set the price of a scaled AI or platform asset. Independent algorithm vendors without an installed-base partner now face a narrower path to scale.

What Is the Digital Pathology Market?
Digital pathology refers to the scanning of glass histology slides into whole-slide images that pathologists read, share and analyse on screen instead of under a microscope. Why now? Because the microscope can't keep up. In Labcorp's 2026 survey of 148 U.S. pathologists, 59% named digital pathology the most effective answer to workforce shortages, and FDA-cleared scanners, viewers and AI quality-control tools are finally arriving as complete systems rather than parts. The market covers whole-slide scanners, image management and AI software, storage and communication systems, and implementation services. Vectomat Insights values it at USD 1,378.5 Mn in 2025, rising to USD 4,175.6 Mn by 2035.
How Is the Digital Pathology Market Segmented?
Software & Analytics takes the biggest slice of 2025 revenue at 42.0%, and it's the part of the stack that renews every year. Scanners come next at 34.0%. The real momentum is in storage: Storage & Communication Systems grows at 17.41% a year, because a fully digital lab produces petabytes of slide images. By application, Cancer Diagnosis leads at 46.0%, but drug developers are closing in fast, and Drug Discovery & Development overtakes it in value by 2035. Hospitals & Diagnostic Labs already make up half of all spending, and Proscia's August 2026 clearance for cloud-hosted primary diagnosis shows where those labs are heading.
This report segments the Digital Pathology market as follows:
- By Product: Software & Analytics, Scanners, Storage & Communication Systems, Services
- By Application: Cancer Diagnosis, Drug Discovery & Development, Disease Research, Others (Education and training, clinical diagnostics for non-cancer disease, and veterinary/forensic pathology)
- By End User: Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Academic & Research Institutes
- By Deployment: On-Premise, Cloud-Based, Hybrid
- By Region: North America, Europe, Asia Pacific, Latin America, The Middle East, Africa

Which Region Leads the Digital Pathology Market?
North America leads with 40.0% of 2025 revenue, worth USD 551.4 Mn, and the United States accounts for USD 452.1 Mn of that on the back of the deepest bench of FDA-cleared scanners and software anywhere. Europe holds 26.14%, with Germany its largest market at USD 96.8 Mn, while NHS networks in the U.K. are digitising at regional scale. Asia Pacific, at 23.0%, is the fastest-growing region: South Korea is set to grow 13.9% a year and Japan 12.0%, as hospitals add capacity and local AI developers mature. Latin America (5.0%), the Middle East (3.05%) and Africa (2.81%) are smaller markets where telepathology, not AI, is the first use case.

Digital Pathology Market Growth Drivers
Pathologist Shortages and Remote Sign-Out — Pathologists can't keep pace with biopsy volumes, and 59% of U.S. pathologists in Labcorp's 2026 survey named digital pathology as the fix. MedStar Health's April 2026 AISight Dx rollout shows health systems acting on it.
FDA-Cleared, End-to-End Clinical Systems — Regulators are now clearing whole systems, not just scanners. Leica Biosystems won three FDA 510(k) clearances in one August 2026 announcement, including AI software that checks slide quality on the scanner.
Consolidation Bringing AI Inside Large Diagnostics Vendors — Diagnostics majors are buying AI instead of building it. Roche agreed to acquire PathAI for up to USD 1.05 Bn in May 2026, and Agilent has since closed its October 2026 deal for Proscia.
Time is the new currency in pathology.
Digital Pathology Market Challenges to Growth
High Capital Cost and Missing Reimbursement — Going digital is expensive, and payers aren't covering it yet. In Labcorp's 2026 survey, 57% of U.S. pathologists flagged capital cost and 66% flagged AI costs with no matching reimbursement.
Data Storage and IT Infrastructure Burden — Every scanned slide is a gigabyte-scale file, and many hospital data centres weren't built for that. It's no accident that storage is the fastest-growing product line, at 17.41% a year.
Even with those cost and infrastructure hurdles, Vectomat Insights expects the market to triple, from USD 1,378.5 Mn in 2025 to USD 4,175.6 Mn by 2035.
What Industry Leaders Are Saying About the Digital Pathology Market
A cloud-enabled deployment reduces reliance on on-premise infrastructure.
Digital pathology is quickly becoming the foundation for pathology data generation, analysis and application.
Digital pathology is a critical enabler of our mission to give MedStar patients faster, more consistent diagnoses.
Report Segmentation & Scope
| Vectomat Insights | Market & Reports — Report Segmentation & Scope | |
|---|---|
| Scope Included in the Study | |
| By Product |
|
| By Application |
|
| By End User |
|
| By Deployment |
|
| Regional Analysis | |
| North America | The U.S., Canada, Mexico |
| Europe | Germany, France, U.K., Italy, Spain, Russia, BENELUX, Sweden, Denmark, Poland, Austria, Rest of Europe |
| Asia Pacific | China, Japan, India, South Korea, Australia, Thailand, Indonesia, Vietnam, Malaysia, Philippines, Taiwan, Rest of Asia Pacific |
| Latin America | Brazil, Argentina, Colombia, Chile, Peru, Rest of Latin America |
| The Middle East | GCC (Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, Oman), Israel, Turkey, Iran, Rest of Middle East |
| Africa | South Africa, Egypt, Nigeria, Algeria, Morocco, Rest of Africa |
| Note: The scope can be further tailored as per your specific requirement. Contact sales@vectomatinsights.com | |
Who Are the Leading Companies in the Digital Pathology Market?
Key players operating in the Global Digital Pathology market include Leica Biosystems (Danaher) (Germany), Roche Diagnostics (Switzerland), Philips (Netherlands), Hamamatsu Photonics (Japan), Agilent Technologies (U.S.), PathAI (U.S.), Tempus AI (Paige) (U.S.), Proscia (U.S.), Sectra (Sweden), Ibex Medical Analytics (Israel), Aiforia Technologies (Finland), Visiopharm (Grundium) (Denmark), Indica Labs (U.S.) and OptraSCAN (U.S.), among others. It's a market splitting into two camps: scanner makers selling complete cleared systems, and AI specialists looking for a home. Roche's May 2026 deal for PathAI and Agilent's purchase of Proscia show the big diagnostics names buying their way into the second camp. The independents that remain are selling through scanner partners' app stores.
Recent Developments in the Digital Pathology Market
October 2026 — Agilent Technologies: Agreed to acquire digital pathology software provider Proscia for USD 240 Mn upfront plus up to USD 30 Mn in milestone payments, and completed the purchase early in Agilent's fiscal 2027.
September 2026 — Leica Biosystems / Tempus AI: Leica Biosystems added Tempus' Paige PanCancer Detect and Paige Prostate suite to its Aperio AI Store for research use.
August 2026 — Leica Biosystems: Received FDA 510(k) clearance for Aperio iQC DX AI quality-control software, the new Aperio GT 180 DX scanner and an enhanced Aperio GT 450 DX.
May 2026 — Roche: Entered a definitive merger agreement to acquire PathAI in a deal worth up to USD 1.05 Bn, with closing expected in the second half of 2026.
May 2026 — Grundium: Agreed to acquire Danish AI precision pathology software developer Visiopharm, which has 750+ customer accounts in 40+ countries.
March 2026 — Philips: Launched the cloud-enabled Philips IntelliSite Pathology Solution on HealthSuite, hosted on Amazon Web Services, in the U.S. and Canada.
Frequently Asked Questions
What is the size of the global digital pathology market?
The Global Digital Pathology market was worth USD 1,378.5 Mn in 2025 and is forecast to reach USD 4,175.6 Mn by 2035, an 11.72% CAGR over 2026–2035. Software & Analytics is the largest product segment at 42.0% of revenue, and North America is the largest region at 40.0%. Growth comes from pathologist shortages, FDA-cleared end-to-end systems and the move to cloud archives, according to Vectomat Insights.
What is driving growth in the digital pathology market?
Three forces stand out. Pathologist shortages are pushing labs toward remote sign-out, with 59% of U.S. pathologists in Labcorp's 2026 survey naming digital pathology the best answer. FDA clearances now cover whole systems, including Leica's AI quality-control software cleared in August 2026. And large diagnostics firms are buying AI specialists, led by Roche's planned PathAI acquisition, so buyers face fewer integration risks, according to Vectomat Insights.
Which region leads the digital pathology market?
North America leads with a 40.0% share of 2025 revenue, worth USD 551.4 Mn, and the United States alone accounts for USD 452.1 Mn. Europe follows at 26.14% and Asia Pacific at 23.0%. Asia Pacific is the fastest-growing region, with South Korea forecast at a 13.9% CAGR and Japan at 12.0% through 2035, ahead of the U.S. at 10.5%, according to Vectomat Insights.
Which product segment dominates the digital pathology market?
Software & Analytics dominates with 42.0% of 2025 revenue, or USD 579.0 Mn, because image management, viewer and AI licences renew every year across the installed scanner base. Scanners hold 34.0% and grow at 13.89% a year. Storage & Communication Systems is the fastest-growing product category at a 17.41% CAGR, reaching USD 960.5 Mn by 2035 as slide archives grow, according to Vectomat Insights.
Who are the leading companies in the digital pathology market?
Leading companies include Leica Biosystems, Roche Diagnostics, Philips, Hamamatsu Photonics and Agilent Technologies on the scanner and platform side, and PathAI, Tempus AI (Paige), Ibex Medical Analytics and Aiforia Technologies in AI. Proscia, Sectra and Indica Labs compete in image management. Consolidation is reshaping the field, with Roche buying PathAI and Agilent buying Proscia in 2026, according to Vectomat Insights.
How can I access the full VMI Digital Pathology market report?
The full report, with 300+ pages, 96 tables and 70 figures, is available from Vectomat Insights in PDF format. It covers four segmentation dimensions, six regions and 35+ countries, and profiles 14 companies, from scanner makers to AI developers. You can request a free sample, ask for customization or buy the report at www.vectomatinsights.com, or email sales@vectomatinsights.com, according to Vectomat Insights.
Access the Complete Digital Pathology Market Report
300+ pages | Global coverage | PDF | 2026
Contact: sales@vectomatinsights.com
About Vectomat Insights
Vectomat Insights is an independent market research firm. Our analysts build every market model in-house, from company revenues, government and regulatory data, and interviews with industry participants, and each report is reviewed by a senior analyst and fact-checked before publication.
Contact: Vectomat Insights | Email: sales@vectomatinsights.com | Website: www.vectomatinsights.com · +1 416-876-0312